Patent settlement agreements are commercial deals to settle patent-related disputes between originator and generic or biosimilar companies. Particularly problematic from a competition law/antitrust perspective are so called "pay-for-delay" agreements, which may restrict generic or biosimilar market entry in exchange for benefits transferred from the originator to the generic or biosimilar company. As emphasized by the EU-Commission “such agreements may result in delayed market entry of cheaper generic medicines, to the detriment of patients and taxpayers financing the health systems.” Hence, these types of agreements have been investigated by competition authorities on both sides of the Atlantic. In this webinar, we will shed light on pay for delay settlements both from an intellectual property and competition law perspective, and will discuss the implications of the recent case law by the European Court of Justice in Case C-307/18 UK Generics and Case C-591/16 P Lundbeck v Commission for the pharmaceutical sector and the right balance between IP protection and competition law more generally.